Table 1. Clinical studies in which Intanza 9 μg was evaluated in adults 18 to 59 y of age.
Clinical trial registration no. | Influenza season | Phase | Number of subjects | Reference |
---|---|---|---|---|
NCT00703651 |
2005/06 (year 3 of 3)a |
II |
828 |
Beran et al. 200955 |
NCT00258934 |
2005/06 |
II |
978 |
Leroux-Roels et al. 200856 |
NCT00383539 | 2006/07 | III | 2255 | Arnou et al. 201057 |
a The final version of Intanza 9 μg was used only in the last year of this 3-y study.